# Trial design & development strategy
> Development choices tested against the questions the evidence will have to answer.
Source: https://www.visfo.health/projects/trial-design-development-strategy
Tags: Sprint

_Development choices tested against the questions the evidence will have to answer._

Strategic input into trial design and development choices: endpoints, comparators, populations and study sequencing, tested against regulatory, HTA and payer expectations. Advisory support alongside your clinical and regulatory teams, not a substitute for them.

## What it is

Strategic input into the choices that determine whether a trial answers the questions decision-makers will actually ask: endpoints, comparators, populations, subgroups and the sequencing of studies across the programme.

We work alongside your clinical, regulatory and biostatistics teams. Protocol authorship, statistical analysis planning and trial operations remain with them or with a CRO; our role is to test the design against downstream regulatory, HTA and payer expectations while those choices are still open.

## How we run it

1. **Frame** — Agree the target profile, the decisions the programme has to support, the markets in scope and where our input starts and stops alongside your clinical and regulatory teams.

2. **Ingest** — Pull the draft design, competitor and precedent trial designs, prior HTA critique of comparable programmes and the relevant guidance into one comparison.

3. **Synthesise** — Test endpoint, comparator and population choices against regulatory, HTA and payer expectations. Surface where a design choice creates a downstream evidence problem, and the options for avoiding it.

4. **Deliver** — Ship the design review with recommendations, the precedent evidence behind them and a working session with clinical, regulatory and access.

## What you get

- Design review against regulatory, HTA and payer expectations

- Endpoint, comparator and population options with trade-offs

- Precedent analysis from comparable programmes and prior critique

- Downstream evidence risks named early, with mitigations

- Working session with clinical, regulatory and access